EMA committee recommends cenegermin for neurotrophic keratitis

Article

A committee of the European Medicines Agency has recommended approval of cenegermin (Oxervate, Dompé) eye drops for neurotrophic keratitis.

A committee of the European Medicines Agency has recommended approval of cenegermin (Oxervate, Dompé) eye drops for neurotrophic keratitis.

There is no effective therapy available for this debilitating condition and it is extremely rare, affecting only five in 10,000 people.

Because of this, the agency designated cenegermin an orphan drug in 2015, and the Committee for Human Medicinal Products (CHMP) completed its review through an accelerated assessment, beginning in November 2016 and ending on 18th May this year.

"We welcome the CHMP opinion with great satisfaction,” said Dompé’s Chief Executive Officer Eugenio Aringhieri in a press release.

In neurotrophic keratitis, damage to the trigeminal nerve or its branches causes loss of sensation in the cornea.

The initial damage can result from herpes simplex and herpes zoster viral infections, trigeminal neuralgia surgery, acoustic neuroma, and toxicity from chronic use of topical ocular medications.

The sensory neurons in the cornea directly influence the integrity of the corneal epithelium. Without them epithelial cells swell, lose microvilli, and produce abnormal basal lamina. This can slow mitosis, leading to epithelial breakdown.

This makes the cornea prone to injury, which can lead to corneal ulcers, perforation, infection, and scarring.

Currently, there are no medical treatments that can induce corneal healing in patients with neurotrophic keratitis, though discontinuation of medications that have caused the syndrome may help. There is also no medication currently available that can restore decreased corneal sensitivity.

Naturally occurring protein

Cenegermin is the recombinant version of the human nerve growth factor (NGF) discovered by Nobel Laureate Dr Rita Levi-Montalcini. This protein is naturally produced by the human body and is involved in the development, maintenance, and survival of nerve cells.

Dompé produces cenegermin through recombinant DNA technology, with the introduction of a gene (DNA) into bacteria causing them to produce the human NGF.

Administered in the form of eye drops to patients with neurotrophic keratitis, cenegermin could promote nerve regeneration, leading to repair of the corneal damage.

The CHMP based its recommendation on the results of two phase II clinical trials involving 204 patients with moderate and severe neurotrophic keratitis.

In both studies, after eight weeks a higher number of patients treated with cenegermin experienced complete corneal healing than patients receiving a placebo.

The most common adverse reactions observed with cenegermin included eye pain, eye inflammation, increased lacrimation, eyelid pain, and foreign body sensation in the eye.

“In the future, our goal is to keep investigating its potential in other pathologies, to allow more and more patients to benefit from this innovative therapeutic approach,” Aringhieri said in the press release.

Decision pending

 

Decision pending

If approved, Oxervate eye drops will be available at a dosage of 20 µg/ml. The drug has not yet been granted marketing authorisation in any country.

The CHMP's recommendation will go to the European Commission for a decision on to grant European Union-wide marketing authorisation, while the Committee for Orphan Medicinal Products will determine whether to maintain orphan designation.

Dompé is also exploring the use of cenergermin in other optic neuropathies, such as retinitis pigmentosa, glaucoma, dry eye syndrome, and retinitis pigmentosa.

Meanwhile, researchers at Yamaguchi University and Hiroshima University are pursuing a similar approach to the treatment of neurotrophic keratitis using a combination of the neurotransmitter substance P and insulin-like growth factor 1 (IGF-1).

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.